Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Padmanabha Das, K
In March 2024, the FDA further approved Wegovy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
at the end of the treatment, a 2.3 point improvement was noted in the exenatide group compared with a 1.7 point deterioration in the placebo group
A narrative synthesis approach was used to summarize findings across studies due to variability in study designs and outcome measures
US$ 23.19
US$ 29.53
US$ 22.06
US$ 21.35
US$ 28.60
US$ 28.97
